PORTOLA PHARMACEUTICALS INC (NASDAQ:PTLA)
Historical Stock Chart
6 Months : From Jan 2019 to Jul 2019
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola’s president and chief executive officer, will present a corporate overview at Cowen and Company’s 39th Annual Health Care Conference in Boston on Tuesday, March 12, 2019 at 8:40 a.m. ET (5:40 a.m. PT).
Webcast DetailsTo access the live investor webcast on Tuesday, March 12, at 8:40 a.m. ET (5:40 a.m. PT), go to the investor section of the company’s website at http://investors.portola.com. A replay will be available for 30 days.
About Portola Pharmaceuticals, Inc.Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s two FDA-approved medicines are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for patients treated with rivaroxaban or apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding, and Bevyxxa® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness. The company also is advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers.
|Investor Contact:||Media Contact:|
|Cara Miller||Pure Communications|
|Portola Pharmaceuticals ||Portola_Media@purecommunications.com |
|firstname.lastname@example.org || |